Articles from SK pharmteco Inc.

RANCHO CORDOVA, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- SK pharmteco announced today that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This approval confirms that SK pharmteco’s sustainability roadmap aligns with the strict 1.5°C pathway required to fight global climate change.

Innovations in Pharmaceutical Manufacturing: Continuous Manufacturing, Advanced Processing & Scalable Technologies on April 8th to feature top experts

RANCHO CORDOVA, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, today announced a strategic partnership. This collaboration aims to integrate Prozomix’s extensive biocatalyst libraries into SK pharmteco’s small-molecule development and manufacturing services, accelerating the transition to sustainable, efficient pharmaceutical processes.

RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors.

RANCHO CORDOVA, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas.

RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This state-of-the-art plant is now fully operational and prepared to support late-stage and commercial viral vector programs at scale.